多囊卵巢综合征的鹿特丹标准:循证标准吗?
鹿特丹标准由专家会议而非循证治疗指南制定,近十年指导了大量多囊卵巢综合征研究。本文基于预后研究和随机对照试验的现有证据,重新审视该标准在指导不孕女性治疗选择和预测预后方面的优势与局限。
要点
- 鹿特丹标准的制定基于专家会议而非循证治疗指南。
- 该标准在预测生殖预后方面显示出优势。
- 下一步需评估其能否指导不孕症及其他健康方面的治疗选择。
核心结论
- 基于现有临床研究数据,应能确定鹿特丹标准是否为循证标准。
研究设计与样本
- 本文为观点文章,基于预后研究和随机对照试验的现有证据进行论述。
主要发现
- 鹿特丹标准在预测生殖预后方面显示出优势。
- 该标准的制定基于专家会议而非循证治疗指南。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Rotterdam criteria for polycystic ovary syndrome (PCOS) are used by a wide range of medical professionals and researchers. However, the development of these criteria was based on expert meetings and not on evidence-based treatment guidance. Over the last decade, the Rotterdam criteria have been useful in guiding research, and a number of clinical studies on PCOS have been published consequently. We plead to revisit the Rotterdam criteria based on the available evidence in prognostic studies and randomized controlled trials. In this opinion paper, we provide arguments of the strengths and limitations of the Rotterdam criteria in guiding treatment selections and predicting prognoses in women with infertility. While the Rotterdam criteria have shown their advantages in predicting reproductive prognosis, the next step is to evaluate whether they can guide treatment choices in infertility as well as other health aspects of the syndrome. Based on available data in clinical studies, we should be able to determine whether the Rotterdam criteria are evidence-based criteria.
引用
- Wang R, Mol BW. The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria? Hum Reprod. 2016. PMID: 28119448. doi:10.1093/humrep/dew287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。